Skip to content

META English logo

Main menu
    • About us
      • Vision, mission and values
      • Diversity, equity & inclusion
      • Executive Leadership Team
      • Global Leaders
      • Board of Directors
      • Our leaders
    • Environmental, social & governance
    • Policies & positions
    • Suppliers
    • Media
    • Press releases
    • Women’s Health Accelerator
    • Rahet Bally x Organon
    • Investor relations overview
    • SEC filings
  • Join our team

Contact Us

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Crucial Signs of Heart Attacks in Women are Being Missed 78% of the Time

Save Print

December 20, 2024 1:53 pm EDT

Dubai, UAE, November 2024: Early warning signs of a heart attack in women are often missed. Extensive research, encompassing real patient narratives and insights from healthcare professionals indicates alarming results. 78% of cases of women who have a heart attack has been missed, as both patients and healthcare professions miss the crucial signs[1].

Dr. Juwairia AlAli, President of Emirates Cardiac Society, comments: “It is crucial to bridge the significant knowledge gap that exists, particularly in understanding the signs of women’s health issues and promoting early medical intervention. Addressing the lack of studies, especially in bridging the gender data gap, remains a vital aspect of our commitment. With a specialised emphasis on heart diseases, we are dedicated to enhancing research in this field to better serve women’s health needs. While progress is being made, there is still much work to be done to shed light on other Therapy Areas that require increased attention in advancing women’s healthcare.”

The reason why heart attacks in women are often missed, traces back to the 1970’s when medical research predominantly cantered on male physiology following the Thalidomide tragedy, creating a substantial knowledge gap concerning female anatomy and responses.

A renowned global healthcare company dedicated to women’s well-being and committed to being ‘here for her health’ has launched a campaign that shines a light on the medical gender bias affecting women’s cardiovascular health. Its initiative aims to show people across the GCC region, Egypt and Lebanon including doctors and the public, the key signs that are associated with heart attacks in women, which differs greatly from that of men.

Contrary to common misconceptions heart attacks, often associated with chest and arm pain and breathlessness, may cause jaw pain and nausea as early symptoms in women. To address this critical issue, Organon, a leading global healthcare provider has launched ‘Mis[s]diagnosed’. An initiative to bring to light the lesser-known symptoms of heart attacks in women and to prevent misdiagnosis. Collaborating with Arab influencers, healthcare professionals, and women, the aim is to foster extensive discussions and awareness through informative content, and impactful storytelling across the UAE, KSA, Jordan, Lebanon, Egypt, and Bahrain.

Ramy Koussa, Associate Vice President of the META Cluster at Organon, comments “At Organon, our focus is on revolutionising women’s health through dedicated Partnerships, initiatives, conversations and R&D initiatives. Recognising the lack of comprehensive studies on heart disease in women, we are determined to fill this critical gap and improve healthcare outcomes for women worldwide. Our commitment lies in listening to their stories, amplifying their voices, and driving tangible change in the way women’s health is understood and addressed. Organon is determined to empower women and ensure their health needs are at the forefront of medical innovation and research.”

Furthermore, the ‘Mis[s]diagnosed’ campaign has prompted Pharma and healthcare entities to enhance clinical trial diversity and foster more inclusive treatment innovations through IPG Health’s ‘Trial for #ClinicalEquality’ Initiative.

The campaign has also highlighted lesser-known symptoms of female heart attacks, including unusual fatigue, light headedness, upper back pain, jaw pain, neck pain, nausea, feeling of heartburn or indigestion, and discomfort in one or both arms.[2] By raising awareness about these symptoms, the campaign aims to empower women to recognize the signs of heart attacks early and advocate for gender-inclusive healthcare practices.

[1] hs_2018-heart-report_en.ashx (heartandstroke.ca)

[2] About Women and Heart Disease | Heart Disease | CDC

What can we help you find?

Search for:
META English logo

Company

  • About us
  • Our leaders
  • Environmental, social & governance

Resources

  • Patient resources
  • Investor relations
  • Media

Contact us

  • Contact Us
  • Contact information
  • Global locations
  • Forward-Looking Statement
  • cookie policy
  • Privacy
  • Terms of Use
  • Sitemap
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept